

November 24, 2014



## Stellar Biotechnologies to Present at LD Micro Conference

PORT HUENEME, CA -- (Marketwired) -- 11/24/14 -- **Stellar Biotechnologies, Inc. ("Stellar" or "the Company")** (OTCQB: SBOTF) (TSX VENTURE: KLH) announced today the Company's management team will present at the upcoming LD Micro Conference on Tuesday, December 2 at 1:00 p.m. PST.

The conference will be held December 2 - 4, 2014 at the Luxe Sunset Boulevard Hotel in Los Angeles, CA.

### **Stellar Biotechnologies' Presentation Details**

Tuesday, December 2, 2014 @ 1:00 p.m. PST  
Luxe Sunset Boulevard Hotel  
11461 Sunset Boulevard, Los Angeles, CA

### **About LD Micro**

LD Micro is an investment newsletter firm that focuses on finding undervalued companies in the micro-cap space. Since 2002, the firm has published reports on select companies throughout the year. The firm also hosts the LD Micro Invitational. It is a non-registered investment advisor. For more information, please contact 408-457-1042 or visit <http://www.ldmicro.com/>.

To receive timely updates of Stellar Biotechnologies news and events, please register for email alerts by signing up at: <http://ir.stellarbiotechnologies.com/email-alerts>

### **About Stellar Biotechnologies, Inc.**

Stellar Biotechnologies, Inc. (OTCQB: SBOTF) (TSX VENTURE: KLH) is the leader in sustainable manufacture of Keyhole Limpet Hemocyanin (KLH), an important immune-stimulating protein used in wide-ranging therapeutic and diagnostic markets. KLH is both an active pharmaceutical ingredient (API) in many new immunotherapies (targeting cancer, immune disorders, Alzheimer's and inflammatory diseases) as well as a finished product for measuring immune status. Stellar Biotechnologies is unique in its proprietary methods, facilities, and KLH technology. We are committed to meeting the growing demand for commercial-scale supplies of GMP grade KLH, ensuring environmentally sound KLH production, and developing KLH-based active immunotherapies.

Visit [www.stellarbiotech.com](http://www.stellarbiotech.com) and the KLH knowledge base [www.klbsite.org](http://www.klbsite.org).

### **Forward Looking Statements**

This press release may contain forward-looking statements within the meaning of Section

27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by the use of words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," "may," "will," "would," "could," "should," "might," "potential," or "continue" and variations or similar expressions. Readers should not unduly rely on these forward-looking statements, which are not a guarantee of future performance. There can be no assurance that forward-looking statements will prove to be accurate, as all such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results or future events to differ materially from the forward-looking statements. Such risks include, but may not be limited to: general economic and business conditions; technology changes; competition; changes in strategy or development plans; governmental regulations and the ability or failure to comply with governmental regulations; the timing of anticipated results; and other factors referenced in the Company's filings with securities regulators. For a discussion of further risks and uncertainties related to the Company's business, please refer to the Company's public company reports filed with the TSX Venture Exchange and the U.S. Securities and Exchange Commission. All forward-looking statements are made as of the date hereof and are subject to change. Except as required by law, the Company assumes no obligation to update such statements. This press release does not constitute an offer or solicitation of an offer for sale of any securities in any jurisdiction, including the United States. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the information contained in this press release.

***Company Contact:***

Mark A. McPartland

Vice President of Corporate Development and Communications

Phone: +1 (805) 488-2800 ext. 103

[markmcp@stellarbiotech.com](mailto:markmcp@stellarbiotech.com)

[www.stellarbiotech.com](http://www.stellarbiotech.com)

Source: Stellar Biotechnologies, Inc.